June 8, 2022
Rheumatoid arthritis (RA) is the most common inflammatory disease of the joints. Nowadays, there are many therapies that can significantly reduce the symptoms However, bone loss and osteoporosis are still a problem. Most osteoporosis therapies aim to inhibit bone loss, while only a few therapies are able to actively promote the formation of new bone tissue to restore bone structure that has already been lost. Building on previous studies, researchers at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund (IfADo) have taken a closer look at the role of the neurotransmitter dopamine in the bone metabolism of RA patients. They conclude that dopamine can be used for new therapeutic approaches to control bone loss in rheumatoid arthritis.
Continue reading →